Skip to content
Veracyte Announces New Data Characterizing Genomic Alterations in Thyroid Cancer To Be Presented at 89th Annual Meeting of the American Thyroid Association
<< Back
Oct 30, 2019

Veracyte Announces New Data Characterizing Genomic Alterations in Thyroid Cancer To Be Presented at 89th Annual Meeting of the American Thyroid Association

Findings derived from Afirma Xpression Atlas analysis of company’s extensive biorepository of thyroid nodule fine needle aspiration samples

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 30, 2019-- Veracyte, Inc. (Nasdaq: VCYT) announced today that new data advancing the understanding of genomic alterations – specifically, NTRK, RET, BRAF and ALK fusions – that are targeted by new precision medicine therapies for thyroid cancer will be presented at the 89th Annual Meeting of the American Thyroid Association, which will be held October 30-November 3, 2019 in Chicago. The findings will be presented in three posters and are derived from Afirma® Xpression Atlas testing of Veracyte’s extensive biorepository of fine needle aspiration (FNA) samples from patients undergoing evaluation for thyroid cancer.

“We believe our extensive collection of thyroid nodule FNA samples with RNA whole-transcriptome sequencing data uniquely enables us to broaden the scientific understanding of the role of key gene alterations in thyroid cancer,” said Richard T. Kloos, M.D., senior medical director, endocrinology, at Veracyte. “Moreover, as the role of precision medicine in thyroid cancer treatment expands, our Afirma Xpression Atlas helps inform physicians’ treatment decisions for their patients with thyroid cancer using the same minimally invasive sample that is used for initial diagnosis with the Afirma Genomic Sequencing Classifier.”

Following are details of the presentations, which will be presented in the Sheraton Grand Chicago Exhibit Hall:

Title:

Positive Predictive Value of NTRK, RET, BRAF and ALK Fusions in Bethesda III/IV Thyroid Fine-Needle Aspirates

Presenter:

Brendan C. Stack, M.D., University of Arkansas for Medical Sciences

Date/Time:

Friday, Nov. 1, 10:05 a.m.-11:00 a.m. and 12:15 p.m.-1:30 p.m. (Central Time)

Poster #:

Short Call Poster 55

 

 

Title:

Identification of Rare, Canonically Mutually Exclusive Variants in Thyroid FNAs

Presenter:

Bryan R. Haugen, M.D., University of Colorado School of Medicine

Date/Time:

Saturday, Nov. 2, 10:05 a.m.-11:00 a.m. and 11:45 a.m.-1:00 p.m. (Central Time)

Poster #

461

 

 

Title:

NTRK, RET, BRAF and ALK Fusions in Thyroid Fine-Needle Aspirates (FNAs)

Presenter:

Mimi I. Hu, M.D., University of Texas, M.D. Anderson Cancer Center

Date/Time:

Saturday, Nov. 2, 10:05 a.m.-11:00 a.m. and 11:45 a.m.-1:00 p.m. (Central Time)

Poster #

462

About Afirma

The Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas provide physicians with a comprehensive solution for a complex landscape in thyroid nodule diagnosis. The Afirma GSC was developed with RNA whole-transcriptome sequencing and machine learning and helps identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to help patients avoid unnecessary diagnostic thyroid surgery. The Afirma Xpression Atlas provides physicians with genomic alteration content from the same fine needle aspiration samples that are used in Afirma GSC testing and may help physicians decide with greater confidence on the surgical or therapeutic pathway for their patients. The Afirma Xpression Atlas includes 761 DNA variants and 130 RNA fusion partners in over 500 genes that are associated with thyroid cancer.

About Veracyte

Veracyte (Nasdaq: VCYT) is a leading genomic diagnostics company that improves patient care by providing answers to clinical questions that inform diagnosis and treatment decisions without the need for costly, risky surgeries that are often unnecessary. The company's products uniquely combine RNA whole-transcriptome sequencing and machine learning to deliver results that give patients and physicians a clear path forward. Since its founding in 2008, Veracyte has commercialized seven genomic tests and is transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, the ability of Veracyte’s Afirma Xpression Atlas to analyze FNA samples to help diagnose thyroid cancer, the expected impacts of Veracyte’s collaboration with Johnson & Johnson in developing interventions for lung cancer, on Veracyte’s financial and operating results, on the timing of the commercialization of the Percepta classifier, and on the size of Veracyte’s addressable market. Forward-looking statements are neither historical facts nor assurances of future performance, but are based only on our current beliefs, expectations and assumptions. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: our ability to achieve milestones under the collaboration agreement with Johnson & Johnson; our ability to achieve and maintain Medicare coverage for our tests; the benefits of our tests and the applicability of clinical results to actual outcomes; the laws and regulations applicable to our business, including potential regulation by the Food and Drug Administration or other regulatory bodies; our ability to successfully achieve and maintain adoption of and reimbursement for our products; the amount by which use of our products are able to reduce invasive procedures and misdiagnosis, and reduce healthcare costs; the occurrence and outcomes of clinical studies; and other risks set forth in our filings with the Securities and Exchange Commission, including the risks set forth in our quarterly report on Form 10-Q for the quarter ended September 30, 2019. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.

Veracyte, Afirma, Percepta, Envisia and the Veracyte logo are trademarks of Veracyte, Inc.

Source: Veracyte, Inc.

Investors:
Keith Kennedy
Chief Operating Officer and Chief Financial Officer
keith@veracyte.com
650-243-6357

Media:
Tracy Morris
tracy.morris@veracyte.com
650-380-4413